# A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)

> **NCT03843125** · PHASE3 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 1147 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Baricitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03843125
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-09
- **Primary completion:** 2022-04-01
- **Final completion:** 2022-04-01
- **Target enrollment:** 1147 (ACTUAL)
- **Why stopped:** Study terminated due to insufficient evidence to support a positive benefit: risk profile. Safety findings were consistent with previously published OLUMIANT data
- **Last updated:** 2023-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03843125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03843125, "A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT03843125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*